Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
Increasingly, IO researchers and biotech R&D teams are prioritising localised IL-12 delivery mechanisms that target tumours directly. Some approaches have already reached the clinical trial stage, with others not far behind. Currently he is Alkermes’ Oncology Fellow and Head of a Oncology Preclinical Research at the company.
98 
Let's personalize your content